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Edited by Jesus AvilaAbstract Previously we described presenilin-1 (PS1) as a GSK-
3b substrate [Kirschenbaum, F., Hsu, S.C., Cordell, B. and
McCarthy, J.V. (2001) Substitution of a glycogen synthase ki-
nase-3beta phosphorylation site in presenilin 1 separates preseni-
lin function from beta-catenin signalling. J. Biol. Chem. 276,
7366–7375; Kirschenbaum, F., Hsu, S.C., Cordell, B. and
McCarthy, J.V. (2001) Glycogen synthase kinase-3beta regu-
lates presenilin 1 C-terminal fragment levels. J. Biol. Chem.
276, 30701–30707], though it has not been determined whether
PS1 is a primed or unprimed GSK-3b substrate. A means of sep-
arating GSK-3b activity toward primed and unprimed substrates
was identiﬁed in the GSK-3b-R96A phosphate binding pocket
mutant [Frame, S., Cohen, P. and Biondi, R.M. (2001) A com-
mon phosphate binding site explains the unique substrate speci-
ﬁcity of GSK3 and its inactivation by phosphorylation. Mol.
Cell 7, 1321–1327], which is unable to phosphorylate primed
but retains the ability to phosphorylate unprimed GSK-3b sub-
strates. By using wild type GSK-3b, GSK-3b-R96A, and a phar-
macological modulator of GSK-3b activity, we demonstrate that
PS1 is an unprimed GSK-3b substrate. These ﬁndings have
important implications for regulation of PS1 function and the
pathogenesis of Alzheimer’s disease.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The presenilins were initially identiﬁed through genetic link-
age of families with autosomal dominant forms of AD [4], but
have emerged as key components of c-secretase protease
associated with all forms of AD [5,6]. Independent research
has shown that presenilins interact with several proteins
involved in regulating c-secretase activity, cell survival, devel-
opment and signalling events [7,8]. These research reports
demonstrate that presenilins are involved in signalling events
independent of AD-associated activities, and propose that
aberrant biological activities of presenilins within signalling
complexes may be related to the pathogenesis of AD.Abbreviations: PS-1, presenilin-1; NTF, N-terminal fragment; CTF,
C-terminal fragment; APP, b-amyloid precursor protein; GSK-3b,
glycogen synthase kinase-3b
*Corresponding author. Fax: +353 21 490 1382.
E-mail address: jv.mccarthy@ucc.ie (J.V. McCarthy).
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.06.035One presenilin-1 (PS1) interacting protein is glycogen syn-
thase kinase-3b (GSK-3b) [9], primarily characterised through
its involvement in insulin and Wnt signalling [10,11]. Aberrant
GSK-3b activity and substrate phosphorylation have also been
attributed to the pathogenesis of AD [9,12–14]. GSK-3b is
ubiquitously expressed with high expression levels in the brain
where it localises predominantly in neurons [15]. GSK-3b is
functionally important in the brain where, through phosphory-
lation, it regulates several substrates including tau and the
transcription factors, b-catenin and cAMP-response element-
binding protein [11]. The possibility that GSK-3b regulates
presenilins function was demonstrated following the identiﬁca-
tion of conserved GSK-3b consensus phosphorylation sites in
PS1 [1,2]. Previously, we reported that phosphorylation of
PS1 at one of these GSK-3bmotifs mediates the interaction be-
tween PS1 and b-catenin [1], while phosphorylation at a second
motif alters the turnover of PS1 C-terminal fragment (CTF) [2].
GSK-3b activity and phosphorylation of substrates is regu-
lated at many levels, including serine and tyrosine phosphory-
lation of GSK-3b, its subcellular compartmentalisation,
interactionwith other proteins, aswell as diﬀerential recognition
of substrates through an independent prior priming phosphory-
lation event [10,11,13]. Although numerous GSK-3b substrates
have been identiﬁed, the GSK-3b recognised consensus sites are
not uncomplicated [10,11,13]. GSK-3b can directly phosphory-
late substrates, such as axin and tau, while in other cases the
GSK-3b substrate must ﬁrst be pre-phosphorylated (primed)
at a site that is four amino acids C-terminal to the target GSK-
3b site. This primes the substrate for phosphorylation by
GSK-3b [3,16,17], and thereby serves to regulate phosphoryla-
tion of certain substrates. Although there are data demonstrat-
ing that PS1 is a GSK-3b substrate [1,2], whether it is a primed
or unprimed substrate of GSK-3b has not been determined.
The aim of this study was to gain insight into the regulation of
GSK-3b-mediated phosphorylation of PS1 in intact cells.2. Materials and methods
2.1. Cell culture
Human embryonic kidney (HEK) 293T cells were grown in Dul-
becco’s modiﬁed Eagle’s medium (DMEM), supplemented with 10%
(v/v) foetal bovine serum, 2 mM L-glutamine, and 50 units/ml penicillin
and 50 lg/ml streptomycin. Cells were maintained in a humidiﬁed 37 C
incubator with 5% CO2. Transfection was carried out on subconﬂuent
HEK293T cultures using the calcium phosphate precipitation method.
2.2. Expression vector construction
CDNA’s encoding PS1 or PS1-phosphomutant [1,2] were ampliﬁed
by standard PCR techniques and subcloned into pcDNA3. The primer
pairs were: 5 0-CGGGGTACCGCCATGACAGAGTTACCTGCAC-
CGTTGTCC-3 0 and 3 0 GTTAATCGTAAGGTAGTTAAAATATA-blished by Elsevier B.V. All rights reserved.
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Dundee provided pCMV-GSK3b-Glu-Glu and pCMV-GSK3b-R96A-
Glu-Glu and Dr. Thilo Hagen provided the HA-epitope tagged b-cate-
nin construct.
2.2.1. Coimmunoprecipitation and Western blot analysis. For coim-
munoprecipitation, HEK293T cell culture were washed twice with ice-
cold phosphate-buﬀered saline and lysed in 1 ml of lysis buﬀer 50 mM
HEPES, 150 mM NaCl, 1 mM EDTA, 0.1% Nonidet P-40, 1 mM so-
dium orthovandate and protease inhibitor mixture (Complete, Roche
Molecular Biochemical’s). Cells were lysed on ice for 30 min, spun at
14,000 rpm for 10 min, and supernatants were collected. Lysates were
normalized using the bicinchonic acid (BCA) method (Pierce). Lysates
were pre-cleared for 1 h with 30 ll Protein-G agarose beads (Pierce).
Lysates were immunoprecipitated with 4 lg monoclonal anti-PS1 anti-
body and immunoprecipitates were washed three times in lysis buﬀer.
Samples were resolved by SDS–PAGE, transferred to PVDF (Milli-
pore) or nitrocellulose membrane (Schleicher and Scheull Bioscience).
For Western blots, lysis buﬀer was supplemented with sodium ﬂuoride
and lysates were prepared in an identical manner. Blots were subjected
to Western blot analysis with the indicated antibodies and proteins
were detected with the ECL reagent (Amersham). Monoclonal PS1
antibody (3.6.1) was previously described [1,2] and others obtained
from commercial sources; Rat anti-human PS1-N-terminal fragment
(NTF) (Chemicon), anti-b-Catenin and GSK-3b (Transduction Labo-
ratories); anti-Glu-Glu (Covance) and anti-b-actin (Sigma).
2.3. Pharmacological inhibition of GSK-3b
Subconﬂuent HEK293T cultures were transfected with pCMV-
GSK3b-Glu-Glu using the calcium phosphate precipitation method.Fig. 1. Sequence analysis of presenilins hydrophilic loop domain. (A)
sequence homology across species. Alignments were done with AlignX
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softw
predicte
howingTwenty-four hours post-transfection cell cultures were stimulated with
either 25 lM SB-415286 (Biomol) for 4 h or with an equivalent volume
of DMSO. Lysis and Western blot analysis was performed as described
above.3. Results
3.1. PS1 contains consensus GSK-3b phosphorylation sites
PS1 and PS2 encode structurally similar proteins that
share a high degree of homology. Each is predicted to con-
tains six or eight transmembrane domains with both N- and
C-terminal hydrophilic regions and a large hydrophilic loop
domain [18]. Alignment of the loop domain of PS1 from sev-
eral species revealed the presence of three GSK-3b consensus
phosphorylation sites [1], two of which are conserved in all
examined species (Fig. 1A). The sequence S/TXXXS/T is
known to be a consensus sequence for a GSK-3b phosphor-
ylation site. In the loop region of PS1 there are three possi-
ble GSK-3b phosphorylation sites: TERES324, STPES357 and
SATAS401. Of these sites only STPES357 and SATAS401 are
conserved across all examined species. Fig. 1B shows an
alignment of PS1 and PS2 loop domains and demonstrates
that neither of the GSK-3b phosphorylation sites is present
in PS2.ce alignment of the hydrophilic loop domain of PS1 and its amino acid
are (Vector NTI). Residues, which ﬁt the consensus sequence for GSK-
d protein kinase A and C phosphorylation sites are also indicated (*).
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Fig. 3. Activity of GSK 3b-R96A mutant. A HEK293T cells were
transfected with HA-b-catenin and cotransfected with GSK-3b, GSK-
3b-R96A as indicated. Cell lysates were analysed by SDS–PAGE and
immunoblotted with HA, b-actin and Glu-Glu antiserum.
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It has been shown that mutation of arganine 96 to alanine
(R96A) in GSK-3b compromises the integrity of its phos-
phate-binding pocket, and thereby selectively disrupts GSK-
3b activity towards primed substrates [3]. To determine
whether GSK-3b could phosphorylate endogenous PS1 when
the phosphate-binding pocket of GSK-3b is disrupted, cells
were transfected with GSK-3b or GSK-3b-R96A mutant. Cell
lysates were collected and immunoblotted with an anti-PS1
antibody, which recognises PS1-CTF. In the absence of exog-
enous GSK-3b, endogenous PS1-CTF migrated as a predomi-
nant single band (Fig. 2A). Coexpression of either wild type
GSK-3b or GSK-3b-R96A resulted in a decrease in the electro-
phoretic mobility of a proportion of PS1-CTF. In contrast,
transfection of either wild type GSK-3b or GSK-3b-R96A
had no observable eﬀect on the electrophoretic mobility of
PS1-NTF (Fig. 2A). Such a reduction in electrophoretic mobil-
ity is characteristic of PS1 phosphorylation by GSK-3b and
other kinases [1,2,19–22]. In all cases wild type GSK-3b or
GSK-3b-R96A were expressed at similar levels (Fig. 2A, lower
panel). Because GSK-3b-R96A only phosphorylates unprimed
sites, these results suggest that PS1 is an unprimed substrate of
GSK-3b. To determine more formally that this GSK-3b in-
duced reduction in electrophoretic mobility is due to phos-
phorylation, we treated samples of the transfected cells
lysates with the potent and selective GSK-3b inhibitor, SB-
415286. This treatment lead to a disappearance of the slower
migrating endogenous PS1-CTF species (Fig. 2B), thereby ver-
ifying that the changed migration pattern was due to GSK-3b
mediated phosphorylation of PS1-CTF. As reported previ-
ously [23], and demonstrating the functionality of SB-415286
as a GSK-3b inhibitor, inhibition of GSK-3b activity resulted
in a parallel and signiﬁcant increase in the stability of b-catenin
(Fig. 2B, lower panel). Consistent with previous reports [23],
GSK-3b-R96A acted as a dominant-negative of endogenousA B
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Fig. 2. GSK-3b and GSK 3b-R96A induces phosphorylation of endog
overexpressing GSK-3b or GSK 3b-R96A. (B) GSK-3b induced phosphoryl
SB-415286 for 4 h) of GSK-3b. Cell lysates were analysed by SDS–PAGE a
b-actin antiserum.GSK-3b function, and also increased steady state levels of b-
catenin (Fig. 3) demonstrating functionality of all constructs
used in this study. Cells were transfected with HA-epitope-
tagged b-catenin and cotransfected with GSK-3b or GSK-
3b-R96A. Cell lysates were collected and immunoblotted with
anti-HA or Glu-Glu antibody. The transfected proteins were
much more abundant compared with endogenous GSK-3b
protein, thus allowing functionality of the mutant proteins.
In previous studies we reported the identiﬁcation and func-
tional characterization of three conserved GSK-3b consensus
phosphorylation sites within the hydrophilic loop domain of
PS1 [1,2]. Site-directed mutagenesis, together with in vitro
and in vivo phosphorylation assays, indicated that PS1 residues
353–357 and 397–401 are GSK-3b phosphorylation sites. WeB-415286 (μM)
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Fig. 4. Overexpression of GSK-3b and GSK-3b-R96A induce phosphorylation of exogenously expressed wild type PS1 but not PS1-phosphomutant.
Cell lysates were analysed by SDS–PAGE and immunoblotted with PS1-CTF, PS1-NTF, GSK3b and b-actin antiserum.
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on phosphorylation of exogenously expressed wild type PS1
and PS1-phosphomutant, mutated at all GSK-3b phosphory-
lation sites (T320R, S324A, S353A, S357A, S397A and
S401R). Cotransfection of GSK-3b or GSK-3b-R96A did re-
duce the migration of a proportion of exogenous wild type
PS1-CTF (Fig. 4). In contrast, cotransfection of wild type
GSK-3b or GSK-3b-R96A had no observable eﬀect on the
electrophoretic mobility and phosphorylation of PS1 mutated
at all three potential GSK-3b phosphorylation sites.IgG50
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Fig. 5. Coprecipitation of PS1 with GSK-3b proteins. Cells were
cotransfected with PS1 and GSK-3b or GSK-3b-R96A as indicated.
Cell lysates were immunoprecipitated with PS1-NTF and analysed by
SDS–PAGE and immunoblotting with Glu-Glu antiserum. Lower
panels indicate equal expression of overexpressed proteins.3.3. PS1 associates with GSK-3b and GSK3b-R96A
GSK-3b has previously been shown to phosphorylate and
coimmunoprecipitate with its substrates PS1 and b-catenin
[9,17], where the interaction between GSK-3b and PS1 has
been mapped to PS1-NTF. To determine whether GSK-3b-
R96A could interact with PS1, HEK293T cell cultures were
transiently transfected with PS1 and cotransfected with empty
vector, wild type GSK-3b or GSK-3b-R96A. Immunoprecipi-
tation of PS1 quantitatively coprecipitated wild type GSK-3b
(Fig. 5) and consistent with our conclusion that PS1 is an un-
primed GSK-3b substrate, PS1 also coimmunoprecipitated
GSK-3b-R96A.4. Discussion
The aim of this study was to gain insight into the regulation
of GSK-3b-mediated phosphorylation of PS1 in intact cells.
Here we clearly demonstrate that GSK-3b-mediated phos-
phorylation of PS1 at (320–324; 353–357; 397–401) does not
require a prior priming phosphorylation event and thereby
identiﬁes PS1 as an unprimed GSK3b substrate.
Antagonising the production of amyloid-b peptides by inhib-
iting presenilin-mediated c-secretase activity is currently being
pursued as a therapeutic strategy for the treatment of AD.
The integrity of presenilins hydrophilic loop domain is required
for its role in c-secretase activity and b-amyloid precursor pro-
tein (APP) cleavage, though we have previously demonstrated
that mutation of the potential GSK-3b phosphorylation sites
have no eﬀect of APP processing or generation of amyloid-b
peptides [1]. However, disruption of c-secretase function alters
many physiological processes, leading to early lethality in sev-
eral organisms [24]. Knowing that presenilin-mediated c-secre-
tase cleavage is involved in the proteolytic processing of
numerous type-1 integral proteins and interacts with signalling
molecules mediating several cellular functions demands caution
in pursuing this therapeutic strategy [7,8]. The binding of PS1
to speciﬁc proteins has been shown to require the hydrophilic
loop sequence, which contains the three GSK-3b phosphoryla-
C. Twomey, J.V. McCarthy / FEBS Letters 580 (2006) 4015–4020 4019tion sites. Among the major goals of research in this area are
the identiﬁcation of protein kinases and phosphatases that
are involved in the modulation of presenilins or presenilins-
mediated c-secretase activities.
The presenilins are phosphoproteins and have been shown to
be phosphorylated by protein kinases A and C [21,22], GSK-
3b [1,2] and by cyclin dependent kinase 5/p35 (cdk5/p35)
[25]. The eﬀects that phosphorylation by these diﬀerent protein
kinases have on presenilins are beginning to provide informa-
tion on presenilins functional complexity. Presenilins have
been shown to be caspase substrates and involved in apoptotic
cell death. Phosphorylation of PS1 and PS2 CTF at the cas-
pase recognition site regulate its cleavage by caspases and also
alter its functional properties during apoptosis [21,22]. Inde-
pendent studies demonstrate that GSK-3b phosphorylation
of PS1 on serine residue 397 [2] selectively regulates PS1
CTF stability. Additionally, the integrity of a GSK-3b site
on the loop domain of PS1 has been shown to inﬂuence PS1
and its ability to interact with b-catenin [1,25]. Recently, ele-
gant studies have demonstrated that the interaction between
PS1 and b-catenin is dependent on the presence of a third com-
plex component the cadherins [26]. Both PS1 and b-catenin
bind independently to cadherin which acting as a scaﬀold
brings PS1 and b-catenin into close proximity to allow their
association. It is possible that the phosphorylation status of
PS1, as a result of GSK-3b activity could aﬀect the formation
or stability of this PS1/E-cadherin/b-catenin complex.
Increasing evidence suggests that aberrant protein phos-
phorylation/dephosphorylation plays a role in the pathogene-
sis of AD, where abnormal cdk5/p35 and GSK-3b activity
have been implicated in AD [11,12,27] and agents that aﬀect
activity of GSK-3b (lithium) are used in the treatment of
AD [28]. PS1, by association with the p85 subunit of phospha-
tidylinositol 3-kinase (PI3-kinase), promotes cadherin/PI3-ki-
nase association [14] and inﬂuences the downstream
phosphorylation status of Akt, GSK-3b and tau, while PS1-
familial Alzheimer’s disease mutants through the PI3-kinase/
Akt pathway lead to an upregulation of GSK-3b activity. It
is unclear what, if any, eﬀect either abrogation or promotion
of GSK-3b phosphorylation of PS1 would have on its associ-
ation with the p85 subunit, binding to the cadherins or on
downstream signalling. Mutating the sites however, had no
eﬀect on b-catenin half-life or stability [1], which indicate that
these sites do not inﬂuence the PI3-kinase/Akt signalling
pathway.
In the pathogenesis of AD increased cdk5/p35 and GSK-3b
activity are attributed to the hyperphosphorylation of tau and
possibly other substrates, suggesting that changes in phosphor-
ylation status of certain proteins modulate the progression of
AD. Indeed, since we show that PS1 is an unprimed substrate
for GSK-3b phosphorylation and its functions are regulated
by GSK-3b phosphorylation, alterations in GSK-3b activity
could lead to changes in presenilins function that could further
contribute to the pathogenesis or progression of AD.
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